Equities

Stereotaxis Inc

Stereotaxis Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.26
  • Today's Change0.41 / 22.16%
  • Shares traded992.09k
  • 1 Year change+53.74%
  • Beta1.4970
Data delayed at least 15 minutes, as of Nov 12 2024 23:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Stereotaxis Inc's revenues fell -4.89% from 28.15m to 26.77m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 18.29m to a larger loss of 20.71m.
Gross margin59.28%
Net profit margin-87.38%
Operating margin-91.43%
Return on assets-49.21%
Return on equity-134.88%
Return on investment-71.93%
More ▼

Cash flow in USDView more

In 2023, Stereotaxis Inc increased its cash reserves by 108.65%, or 10.71m. Cash Flow from Investing totalled 19.77m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 9.14m for operations while cash generated from financing totalled 81.00k.
Cash flow per share-0.2583
Price/Cash flow per share--
Book value per share0.202
Tangible book value per share0.202
More ▼

Balance sheet in USDView more

Stereotaxis Inc uses little or no debt in its capital structure.
Current ratio2.29
Quick ratio1.53
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.